Targeted gene delivery
Right Cell, Right Payload, Right Disease
Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.
Based on innovations conceived at Interius, we can now rethink how genetic medicine can be used to create transformational therapies for our patients.
Phil Johnson, CEO
Core Technologies Enable In Situ Re‑engineering of Cellular Functions
Our lead programs are initially focused on treating hematologic malignancies by leveraging the Interius platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.
We are also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.
Leveraging the Experience of Leading Minds
Prior to assuming his current role at Interius, Phil was the founding CSO, President, and Interim CEO of Limelight Bio from 2016 – 2020. For the three preceding decades, he led large research enterprises at two of the world’s premier academic pediatric hospitals while receiving multiple national honors including election to the American Pediatric Society and being named a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.
Phil received undergraduate and medical degrees from the University of North Carolina and then completed pediatrics residency and infectious diseases fellowship training at Vanderbilt University and the National Institutes of Health. He is considered an international leader in viral vector technology and human gene transfer.
Before joining Interius, Dora served as Vice President of Business Development and Vice President of Operations of Carisma Therapeutics, where she was on the founding team. Prior to the launch of Carisma, Dora managed a portfolio of 60 startup companies at PCI Ventures at the University of Pennsylvania as Director of the UPstart Company Incubator, often acting as “entrepreneur-in-residence” for companies in the life sciences portfolio. She has held roles spanning pre-clinical, early clinical, management and board positions in young companies including NellOne Therapeutics, Cognizance Biomarkers (acquired), CytoVas, LignaMed, Linnaeus Therapeutics Inc., Quantitative Radiology Solutions and Ophidion, Inc. Dora fell in love with early-stage companies while a member of the Health and Life Sciences team at Battelle Ventures, LP, early-stage life science and technology venture capital fund. She serves as founding investment committee member of Nassau Street Ventures. Dora holds a PhD in Molecular Biology from Princeton University.
Mohit is the head of immunology at Interius. He is an experienced and award-winning cancer biologist with an extensive background in immuno-oncology and cell therapy. Mohit is dedicated to advancing therapies to make a positive difference in the lives of others.
Over the past 15 years, Mohit has contributed significantly to advancing techniques and strategies to create novel cancer treatment modalities including cell therapies. He joins Interius from Elicio Therapeutics where he was leading a team developing cancer vaccine and CAR-T programs. Prior to Elicio, he was a Project Leader at Cellectis where he created next-generation allogeneic CAR-T cells and discovered mechanisms underlying CAR-T cells mediated cytokine release syndrome (CRS).
Mohit received his Ph.D. at Southern Illinois University and completed post-doctoral work at Duke University. He has authored over 25 manuscripts in high impact journals and is inventor on multiple patent applications in the field of cell therapy. Mohit is a combat veteran and serves as an officer in the United States Army Reserve.
Govi leads the CMC efforts of Interius BioTherapeutics. A virologist with over 15 years of experience in lentivirus and other virus vector/vaccine discovery and process development, Govi most recently was heading the Lentivirus Process Development at Janssen, playing a critical role in regulatory submissions for ex vivo CAR-T programs. Prior to that, Govi spent approximately 10 years at Merck Research Laboratories working on a variety of viral vaccine programs. His role in these programs ranged from early discovery, vaccine generation and analytical characterization to process development and large-scale manufacture for clinical supply. Govi’s expertise includes large-scale virus vector and vaccine production, process development, scale-up, and technology transfer. He is well experienced in virus engineering, recombinant virus generation, infectious clone technology and reverse genetics of several families of viruses (positive and negative sense RNA viruses and retroviruses) as well as GLP/GMP operations and regulatory submission authorship.
Govi received his Veterinary medicine degree from Madras Veterinary College, Chennai, India and doctoral degree in the field of Molecular Virology from the University of Maryland, College Park. Subsequently, he completed his post-doctoral studies at the Bloomberg School of Public Health, Johns Hopkins University.
During his more than 35 year career in biotechnology, Bruce Peacock has held numerous senior leadership positions, including President and Chief Executive Officer of Adolor Corporation, Alba Therapeutics and Orthovita, Inc., and Chief Financial Officer (CFO) and Business Officer of Ophthotech. For over 10 years, he served as Venture Partner with SV Life Sciences Health Investors. Previously, he was Executive Vice President and Chief Operating Officer of Cephalon Inc. and prior to this, he was CFO at Centocor, Inc. He is a member of the Board of Directors of Ocular Therapeutics, PanOptica and Windtree Therapeutics. Bruce is committed to nurturing young biotechnology companies in Philadelphia: he was instrumental in the growth of Carisma Therapeutics, focused on novel cell therapies for cancer, and of Aro BioTherapeutics, developing targeted genetic medicines. Bruce holds a BA in Business Administration from Villanova University.
Saar is an assistant professor of medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia and in bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cell trials for chronic and acute leukemias. His research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering. Saar is a foremost innovator in the cell and gene therapy space as evidenced by his being one of the most prolific patent inventors in the field globally as well as his creation of two biotherapeutics companies: Carisma Therapeutics, developing macrophage-based cellular therapeutics, and Interius BioTherapeutics, focused on specific in vivo delivery of gene therapies.
Saar obtained his medical degree and PhD in immunology from the University of Melbourne in Australia, and completed a post-doctoral fellowship in cellular therapy at Stanford University.
BOARD OF DIRECTORS
Lonnie serves as our Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a Boston based oncology-focused biopharmaceutical company) and served as CEO until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.
Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder is Executive Chair of Zenas BioPharma, serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and also the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.
Prior to assuming his current roles at Interius, Phil was the founding CSO, President, and Interim CEO of Limelight Bio from 2016 – 2020. For the three preceding decades, he led large research enterprises at two of the world’s premier academic pediatric hospitals while receiving multiple national honors including election to the American Pediatric Society and being named a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology. Phil received undergraduate and medical degrees from the University of North Carolina and then completed pediatrics residency and infectious diseases fellowship training at Vanderbilt University and the National Institutes of Health. He is considered an international leader in viral vector technology and human gene transfer.
Ben rejoined Bain Capital in 2018 as a Principal in Life Sciences. He initially joined Bain Capital in 2012 as an Associate on the North America Private Equity team, focused on Healthcare.
From 2014 to 2017, Ben was a Vice President at Paulson & Co., focused on public and private equity investments in Healthcare. From 2017 to 2018, he was a Partner at Soleus Capital, an investment firm focused on public and private equity investments in Life Sciences. Prior to initially joining Bain Capital, Mr. Lund was an Analyst in the Healthcare Investment Banking group at Goldman Sachs.
Ben graduated with Phi Beta Kappa distinction from Princeton University with an AB in Molecular Biology and Neuroscience.
Tomas is currently managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak served as a managing director at RA Capital Management LLC, based in Boston. Tomas also serves on the board of directors of Zenas BioPharma , Dianthus Therapeutics, and Viridian Therapeutics. He received his BA in Neuroscience and Economics from Amherst College.
News and Events
Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo…
Join Us on Our Fantastic Voyage
We are looking for passionate folks who want to make a difference in the world. Talent matters, but so does decorum and compassion. Come join us and become an Interian.
see our open positions